The significant increase in R&D spending and substantial 2026 guidance suggests the company is aggressively advancing its clinical pipeline, particularly with multiple Phase 3 trials. Traders should monitor upcoming clinical readouts, especially the RASolute 302 trial in pancreatic cancer expected in 1H 2026, as key value inflection points.
Price Chart
Executive Summary
Revolution Medicines reported its 2025 financial results, highlighting a $1.1 billion net loss on $987.3 million in R&D expenses as it advances a broad late-stage oncology pipeline. The company maintains a strong $2.0 billion cash position and provided 2026 operating expense guidance of $1.6-$1.7 billion, reflecting continued heavy investment in clinical development.
Key Financial Metrics
Key Facts
- Cash, cash equivalents and marketable securities were $2.0 billion as of December 31, 2025
- R&D expenses were $987.3 million for 2025, up from $595.2 million in 2024
- Net loss was $1.1 billion for 2025, compared to $600.1 million in 2024
- 2026 GAAP operating expenses are guided to be between $1.6 and $1.7 billion
- Company is advancing five ongoing Phase 3 trials with three additional Phase 3 trials planned for 2026
Financial Impact
Increased R&D spend by $395.1 million year-over-year to $987.3 million, with 2026 operating expenses expected to grow to $1.6-$1.7 billion
Risk Factors
- High cash burn rate with $1.1 billion net loss in 2025
- Continued heavy investment with 2026 operating expenses guided at $1.6-$1.7 billion
- Clinical trial readouts may not meet expectations, particularly the pivotal RASolute 302 trial
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-071517 |
| Document: 0001193125-26-071517-index.html | 0001193125-26-071517 |
| Document: 0001193125-26-071517.txt | 0001193125-26-071517 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 16d ago | 144 | $195.92 $190.74 | ▼ −2.64% | ▼ −5.21% | $206.29 (+5.29%) |
Sep 15, 2026 16d ago | 144 | $195.92 $190.74 | ▼ −2.64% | ▼ −5.21% | $206.29 (+5.29%) |
Sep 15, 2026 17d ago | Insider Cluster | $204.86 $190.95 | ▼ −6.79% | ▼ −7.61% | $206.29 (+0.70%) |
Sep 14, 2026 17d ago | Insider Cluster | $204.86 $192.86 | ▼ −5.86% | ▼ −7.98% | $206.29 (+0.70%) |
Aug 26, 2026 5w ago | 8-K | $215.44 $209.23 | ▼ −2.88% | ▼ −2.76% | $206.29 (−4.25%) |
Aug 26, 2026 5w ago | Press Release | $215.44 $209.23 | ▼ −2.88% | ▼ −2.76% | $206.29 (−4.25%) |
Aug 25, 2026 5w ago | Insider Cluster | $211.38 $209.87 | ▼ −0.71% | ▼ −0.18% | $206.29 (−2.41%) |
Jul 2, 2026 13w ago | Press Release | $189.24 $191.13 | ▲ +1.00% | ▲ +0.07% | $206.29 (+9.01%) |
Jul 1, 2026 13w ago | Insider Cluster | $187.51 $190.46 | ▲ +1.57% | ▲ +1.31% | $206.29 (+10.02%) |
Jun 22, 2026 14w ago | 8-K | $165.81 $192.62 | ▲ +16.17% | ▲ +16.62% | $206.29 (+24.41%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access